Micro-Flow Imaging (MFI) is a key technology for particle characterization. Compared with light obscuration that has been conventionally used for sub-visible particle testing and conventional light microscopy, MFI technology offers multiple advantages.read more
Solvias achieves solid growth in 2015, driven by innovation, geographic expansion and development of new market segments
Solvias today announced figures for 2015. Revenues rose to CHF 63.9 million, an increase of 5.6% over the previous year with a significant improvement in profitability.read more
Solvias's new Quality Control (QC) department will significantly boost the company's capacity to serve as a “one-stop shop” with fast, high-quality and cost-effective QC, complementing Solvias's established reputation in cutting-edge R&D. Find out all the details in our press release.read more
Valorization of the Primary Building Blocks Ammonia and Acetone Featuring Pd- and Ni-Catalyzed Monoarylations
Recently, there has been significant progress in the monoarylation of ammonia and acetone. Find out how the application of ferrocenyl bisphosphine ligands has enabled remarkable improvements in substrate scope and reaction conditions as well as catalyst costs and availability.read more
The characterization of PEGylated proteins by standard methods is a demanding task due to polydispersity of the PEG chain and protein itself.
Find out about a new approach of reducing the complexity of PEG Erythropoietin for localization and qualification of PEG chains in this presentation.read more
Strategic alliance of Hanson Research, Shimadzu and Solvias AG improves dissolution testing workflow. Here is the announcement published by our new partner Hanson Research concerning this spectacular project.read more
Visit stand 1D45 to discuss your needs and our most recent developments.
Solvias is an experienced full-service provider in contract research, manufacturing, development and analysis. Come and find out what problems we can solve together – we look forward to meeting you!read more
Find out why Solvias is an ideal partner for the catalysis-based manufacture of pharma and fine-chemical products and intermediates.
This feature highlights the essential elements for the successful industrial application of homogeneous and heterogeneous catalysis, where Solvias.read more
Solvias has opened new state-of-the-art kilo lab facilities for the cost-effective manufacturing of catalysts and ligands, intermediates and early stage active pharmaceutical ingredients (APIs). The facilities are configured for process development, scale-up and the production of up to multi-kilogram quantities.read more
Solvias continues to be at the forefront of technological and scientific advances in analytical services, solid-state development and catalysis as well as ligands. We sincerely hope you will enjoy the articles highlighting new developments in quite different business areas.read more
Life Science Leader magazine announces that Solvias is a winner in all five categories of the 2015 CMO Leadership Awards.
Life Science Leader magazine has announced Solvias as an award recipient in all five categories of the annual CMO Leadership Awards. The Life Science Leader’s CMO Leadership Awards are based upon industry research conducted by Nice Insight, who’s market research identified Solvias in the top 10% of pharmaceutical partners …read more
Solvias Group reports solid growth in 2014 and continues its investments in innovative technologies.
Kaiseraugst/Switzerland – Contract research and service provider Solvias today announced sales figures for 2014. Revenues rose by 7.2% over the previous year to CHF 61 million.read more